News & Events
Insight Genetics Presented Presents Posters on Immune Cell Involvement in TNBC at San Antonio Breast Cancer Symposium
Insight Genetics, Inc.’s proprietary Insight TNBCtype™ algorithm was featured in two posters on triple negative breast cancer (TNBC) presented on December 7 at the 2016 San Antonio Breast Cancer Symposium (SABCS).
2015 was an exciting year for Insight Genetics with the formation of new partnerships, continued collaboration with existing partners, expansion of our leadership team, the launch of a CLIA-validated assay for non-small cell lung cancer (NSCLC), presentation of new research findings on triple negative breast cancer (TNBC), and new funding to continue the advancement of the company’s TNBC and NSCLC programs. We look forward to an eventful 2016 as we continue to clinically validate and commercialize our breast and lung cancer assays, adapt these assays for compatibility with liquid biopsies and broader, multi-biomarker panels, expand collaborations with key academic institutions and commercial partners, and extend our services to the pharmaceutical industry.
The Archives of Pathology and Laboratory Medicine recently published an article by a group from the Department of Pathology and Genomic Medicine at Houston Methodist Hospital who performed a clinical validation of the Insight ALK Screen qPCR assay which is manufactured and distributed globally by QIAGEN as ALK RGQ RT-PCR Kit.
Insight Genetics, Inc. today announced that Ronald (Ronnie) Andrews Jr., former president of the Genetic Science Division of Thermo Fisher Scientific, has been named to the company’s Board of Directors. Andrews also joined the company’s base of private investors, in a round of $3 Million growth capital that will allow Insight Genetics to expand and expedite its triple negative breast cancer and non-small cell lung cancer programs. The minimum of $3 million has been closed, with a maximum of $5 million targeted.
Insight Genetics will attend the Association for Molecular Pathology (AMP) 2015 Annual Meeting in Austin, Texas from November 4-7, 2015. At the event, Insight Genetics will be available to discuss its current programs focused on enabling precision medicine in non-small cell lung cancer and triple-negative breast cancer as well as its service offerings including custom assay design and development and specialized pharmaceutical services.